Metagenomi Inc. (Nasdaq: MGX)

https://www.metagenomi.co

LinkedIn: https://linkedin.com/company/metagenomi

At Metagenomi, we are accelerating innovation in cell and gene therapy with a wave of proprietary CRISPR-based systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful therapeutic tools that can be leveraged by partners and fuel our own pipeline of potentially curative medicines. Our goal is to revolutionize gene editing and unlock its power for the benefit of patients around the world. *

	Start	2018-01-01 established (s-off)
	Predecessor	University of California, Berkeley
	Industry	CRISPR gene editing technology
	Industry 2	genomics
	Person	Thomas, Brian C. (Metagenomi 202011 CEO + Co-Founder)
	Person 2	Knowles, Jak (Affini-T Therapeutics 202203 CEO + Co-Founder before Metagenomi 202011– CBO before Leaps by Bayer)

	Region	Emeryville, CA
	Country	United States (USA)
	Street	5959 Horton Street 7th Floor
	City	94608 Emeryville, CA
	Tel	+1-510-871-4880
		Address record changed: 2024-04-26

Basic data	Employees	D: 101 to 500 (2023-12-31)
	Currency	USD
	Annual sales	44,756,000 (revenue, collaboration, consolidated (2023) 2023-12-31)
	Profit	-68,255,000 (2023-12-31)
	Cash	271,172,000 (2023-12-31)

		* Document for »About Section«: Bayer AG. (11/12/20). "Press Release: Metagenomi Closes USD 65 Million Series A Financing Led by Leaps by Bayer and Humboldt Fund". Emeryville, CA & Leverkusen.

		Record changed: 2024-04-26